证券代码：300194 证券简称：福安药业 公告编号：2025-022 福安药业（集团）股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记载、误导性陈 述或者重大遗漏。 一、本期业绩预计情况 项 目 本报告期 上年同期 盈利：10,000 万元–13,000 万元 归属于上市公司股 盈利：21,647.75 万元 东的净利润 本次业绩预告相关财务数据未经注册会计师审计，敬请投资者注意投资风险。 三、业绩变动原因说明 （一）业绩变动情况 - 53.81%。公司业绩下降的主要原因是：随着集采在全国推行，公司主要产品销售价格大 幅度下降，营业收入降低，利润空间承压。 比上年同期下降：39.95% - 53.81% 盈利： 9,100 万元–12,100 万元 扣除非经常性损益 盈利：20,337.34 万元 后的净利润 比上年同期下降：40.50% -55.25% 二、与会计师事务所沟通情况 公司董事会关于2025年半年度业绩预告的情况说明。 特此公告。 福安药业（集团）股份有限公司 董事会 二〇二五年七月十八日 （二）非经常性损益对净利润的影响说明 本报告期，公司预计非经常性损益 ...

Core Viewpoint - The company Fu'an Pharmaceutical (300194) expects a significant decline in net profit for the first half of 2025, primarily due to price reductions in its main products as a result of nationwide centralized procurement [1] Financial Performance - The projected net profit attributable to shareholders for the period from January 1, 2025, to June 30, 2025, is estimated to be between 100 million to 130 million yuan, representing a year-on-year decrease of 39.95% to 53.81% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 91 million to 121 million yuan, reflecting a year-on-year decline of 40.50% to 55.25% [1] Market Conditions - The decline in performance is primarily attributed to the implementation of centralized procurement across the country, which has led to a substantial decrease in the sales prices of the company's main products [1]